Diclofenac toxicity to hepatocytes: a role for drug metabolism in cell toxicity.

Diclofenac, a 2-arylacetic acid, nonsteroidal anti-inflammatory drug, has been reported to cause adverse hepatic effects in certain individuals. To discriminate among possible mechanisms of hepatotoxicity, we examined the effects of diclofenac on human and rat hepatocytes and hepatic cell lines (HepG2, FaO), investigated the major biochemical events in the course of diclofenac cytotoxicity (calcium homeostasis, lipid peroxidation, and mitochondrial dysfunction), and investigated whether cytotoxicity could be related to drug metabolism by cytochrome P-450. Acute diclofenac-induced toxicity in hepatocytes was preluded by a decrease in ATP levels, whereas no significant oxidative stress (decrease in glutathione and lipid peroxidation) or increase in intracellular calcium concentration could be observed at early incubation stages. Diclofenac was more cytotoxic to drug metabolizing cells (rat and human primary cultured hepatocytes) than to nonmetabolizing cell lines (HepG2, FaO). Despite the fact that diclofenac itself was effective in impairing ATP synthesis by mitochondria, we found evidence that toxicity was also related to drug metabolism and was reduced by the addition of cytochrome P-450 inhibitors (proadifen and ketoconazole) to culture medium. The in vitro cytotoxicity correlated well with the formation by hepatocytes of 5-hydroxydiclofenac and, in particular, N,5-dihydroxydiclofenac, a minor metabolite first characterized in this article. Hepatic microsomes showed the ability to both oxidize 5-hydroxydiclofenac to N,5-dihydroxydiclofenac and back reduce the latter to 5-hydroxydiclofenac with the consumption of NADPH. The experimental results suggest that the toxic effect of diclofenac on hepatocytes may be caused by drug-induced mitochondrial impairment, together with a futile consumption of NADPH.

[1]  M. Sulc,et al.  Pharmacokinetics and metabolism of the anti-inflammatory agent Voltaren. , 1978, Scandinavian journal of rheumatology. Supplement.

[2]  S. Ciccolunghi,et al.  Report on a long-term tolerability study of up to two years with diclofenac sodium (Voltaren). , 1978, Scandinavian journal of rheumatology. Supplement.

[3]  W. Richter,et al.  Biotransformation of diclofenac sodium (Voltaren) in animals and in man. I. Isolation and identification of principal metabolites. , 1979, Xenobiotica; the fate of foreign compounds in biological systems.

[4]  M. Brodie,et al.  Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens. , 1980, British journal of clinical pharmacology.

[5]  Á. Montoya,et al.  Effects of benorylate and impacina on the metabolism of cultured hepatocytes. , 1985, Xenobiotica; the fate of foreign compounds in biological systems.

[6]  J. Mcnicholl,et al.  Fatal hepatitis associated with diclofenac. , 1986, Gut.

[7]  D. Schapira,et al.  Diclofenac-induced hepatotoxicity. , 1986, Postgraduate medical journal.

[8]  James B. Mitchell,et al.  Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. , 1987, Cancer research.

[9]  T. Winkler,et al.  A new metabolite of diclofenac sodium in human plasma. , 1988, Xenobiotica; the fate of foreign compounds in biological systems.

[10]  H. Yamada,et al.  Enzymic reduction of N-hydroxyamphetamine: the role of electron transfer system containing cytochrome b5. , 1988, Biochemical pharmacology.

[11]  R. Tsien,et al.  Fluorescent indicators for cytosolic calcium based on rhodamine and fluorescein chromophores. , 1989, The Journal of biological chemistry.

[12]  D. Zakim,et al.  Diclofenac-associated hepatotoxicity. , 1990, JAMA.

[13]  R. Chapman,et al.  Diclofenac associated hepatitis. , 1990, Journal of hepatology.

[14]  R. Sallie Diclofenac hepatitis. , 1990, Journal of hepatology.

[15]  Richard Sailie Letter to the editorDiclofenac hepatitis , 1990 .

[16]  M. Relling,et al.  Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. , 1990, The Journal of pharmacology and experimental therapeutics.

[17]  G. Gores,et al.  Toxic injury from mercuric chloride in rat hepatocytes. , 1990, The Journal of biological chemistry.

[18]  A. Salama,et al.  Autoantibodies and drug‐or metabolite‐dependent antibodies in patients with diclofenac‐induced immune haemolysis , 1991, British journal of haematology.

[19]  A. West,et al.  Reversible hepatitis associated with diclofenac. , 1991, Journal of clinical gastroenterology.

[20]  D. Henry,et al.  Diclofenac hepatitis. , 1991, Gut.

[21]  M. Gómez-Lechón,et al.  Measurement of intracellular LDH activity in 96-well cultures: A rapid and automated assay for cytotoxicity studies , 1991 .

[22]  T. Kunze,et al.  The reduction of 6-N-hydroxylaminopurine to adenine by xanthine oxidase. , 1992, Biochemical pharmacology.

[23]  S. Orrenius,et al.  Calcium-mediated mechanisms in chemically induced cell death. , 1992, Annual review of pharmacology and toxicology.

[24]  D A Smith,et al.  Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. , 1992, Biochemical pharmacology.

[25]  G. Schmitz,et al.  Toxicity of diclofenac to isolated hepatocytes. , 1992, Journal of hepatology.

[26]  X. Ponsoda,et al.  Cocaine hepatotoxicity: two different toxicity mechanisms for phenobarbital-induced and non-induced rat hepatocytes. , 1993, Biochemical pharmacology.

[27]  T. Myers,et al.  Immunochemical detection of liver protein adducts of the nonsteroidal antiinflammatory drug diclofenac. , 1993, Chemical research in toxicology.

[28]  U. Boelsterli,et al.  Diclofenac covalent protein binding is dependent on acyl glucuronide formation and is inversely related to P450-mediated acute cell injury in cultured rat hepatocytes. , 1993, Toxicology and applied pharmacology.

[29]  T. Leemann,et al.  Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. , 1993, Life sciences.

[30]  R. Barr,et al.  Diclofenac induced hepatitis , 1993, Digestive diseases and sciences.

[31]  M. Jurima‐Romet,et al.  Comparative cytotoxicity of non-steroidal anti-inflammatory drugs in primary cultures of rat hepatocytes. , 1994, Toxicology in vitro : an international journal published in association with BIBRA.

[32]  A. Romano,et al.  Positivity of patch tests in cutaneous reaction to diclofenac , 1994, Allergy.

[33]  G. Schmitz,et al.  Failure of calcium antagonistic agents to prevent hepatotoxicity induced by diclofenac. , 1995, Pharmacology & toxicology.

[34]  M. Gómez-Lechón,et al.  Molecular mechanism of diclofenac hepatotoxicity: Association of cell injury with oxidative metabolism and decrease in ATP levels. , 1995, Toxicology in vitro : an international journal published in association with BIBRA.

[35]  K. Tabata,et al.  Local absorption kinetics into the portal system using the portal-venous concentration difference after an oral dose of diclofenac in the awakening rat. Accelerative effect of bile on intestinal absorption of diclofenac. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[36]  M. Gómez-Lechón,et al.  In vitro investigation of the molecular mechanisms of hepatotoxicity , 1996 .

[37]  X. Ponsoda,et al.  Metabolism of aceclofenac in humans. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[38]  J. Uetrecht,et al.  Oxidation of diclofenac to reactive intermediates by neutrophils, myeloperoxidase, and hypochlorous acid. , 1997, Chemical research in toxicology.